Form 4: Black Diamond Therapeutics Director Acquires Stock Options

Garry E. Menzel, a Director at Black Diamond Therapeutics, Inc., acquired 40,000 stock options on June 26, 2026.

Summary

• Garry E. Menzel, a Director of Black Diamond Therapeutics, Inc., was granted 40,000 stock options on June 26, 2026.
• These options have an exercise price of $1.71 and an expiration date of June 25, 2036.
• The shares subject to the option will vest in full on the earlier of June 26, 2027, or the Issuer's next annual meeting of stockholders, provided Menzel continues to serve as a director.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it represents a standard compensation practice for a director, indicating continued engagement but not necessarily a significant change in company performance.

Positives

• Director Garry E. Menzel has acquired a significant number of stock options, indicating confidence in the company's future prospects.
• The acquisition of options aligns the director's interests with those of shareholders, as the value of the options is tied to the company's stock performance.

Risks

• The vesting of the options is contingent upon continued service, meaning any departure from the board before the vesting date would result in forfeiture of the options.
• The value of the options is subject to market fluctuations and the company's performance, which could result in the options expiring worthless if the stock price does not exceed the exercise price.

Future Outlook

The vesting schedule for the stock options suggests a forward-looking expectation of continued service by the director, aligning with the company's long-term strategy.

Industry Context

StockSavvy.ai notes that the granting of stock options to directors is a common practice in the biotechnology sector to incentivize leadership and align their financial interests with shareholder value, especially for companies in development stages.

Stakeholder Impact

• Shareholders: The alignment of director compensation with stock performance can be viewed positively, as it incentivizes the director to act in ways that benefit shareholders.
• Employees: Standard compensation practices for directors can contribute to overall corporate stability and morale.

Next Steps

• Director Garry E. Menzel is expected to continue his service on the board until at least June 26, 2027, for the options to vest.

Key Dates

Keywords

Black Diamond Therapeutics, BDTX, Form 4, Stock Options, Insider Trading, Director Compensation, Securities, Executive Compensation